Trials / Completed
CompletedNCT04773522
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Janssen Pharmaceutical K.K. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talquetamab | Talquetamab will be administered subcutaneously. |
Timeline
- Start date
- 2021-05-20
- Primary completion
- 2022-10-14
- Completion
- 2025-09-04
- First posted
- 2021-02-26
- Last updated
- 2025-10-01
Locations
6 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04773522. Inclusion in this directory is not an endorsement.